Q1 2026 Earnings Call May 4, 2026 4:30 PM EDTCompany ParticipantsTraci McCarty - Group Vice PresidentAlexander Hardy ...
Clinuvel Pharmaceuticals (ASX:CUV) is conducting a Phase III trial to expand the indications for Scenesse (afamelanotide), ...
Marvin T. Milk a.k.a. MM from The Boys is the group's level-headed, loving, and oft-frustrated medic with a God-tier T-Shirt ...
Ibogaine is getting an accelerated federal research push, but the drug is unapproved and understudied and carries a ...
The developer of a drug for the blood cancer myelofibrosis, Syntara (ASX:SNT) has taken the time-honoured route of raising ...
A new FDA regulatory pathway could accelerate approval of psychedelic therapies for resistant depression and PTSD, and ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Embark on a fulfilling pharmacy career with our Pharmacy Technician Training Program. Our 16-week program allows you to gain the skills required for safe patient care. The self-paced format ensures ...
For Immediate Closed Captioning or Audio Description Concerns: Email us at wwjtvclosedcaptioning@cbs.com. For Non-immediate or Written Closed Captioning or Audio Description Complaints: Contact WWJ-TV ...
Hosted on MSN
ASX biotechs near decisive Phase III trial readouts
A cluster of ASX-listed biotech companies is approaching pivotal Phase III trial readouts in 2026, marking the final hurdle before potential regulatory approvals and commercial launches. Success could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results